Amendment No. 1 to the Employment Agreement, dated August 4, 2023, by and between Lipella Pharmaceuticals Inc. and Jonathan Kaufman

Contract Categories: Human Resources - Employment Agreements
EX-10.1 2 g083697_ex10-1.htm EXHIBIT 10.1

Exhibit 10.1




This Amendment No. 1, dated August 4, 2023 (the “Amendment”), to the Employment Agreement entered into as of July 17, 2020 by and between Jonathan Kaufman and Lipella Pharmaceuticals Inc., a Delaware corporation (the “Employment Agreement”).


The parties hereto hereby agree as follows:


1.Section 4.1 of the Employment Agreement is hereby deleted in its entirety and the following is inserted in lieu thereof:


“4.1 Base Salary. The Company shall pay the Executive an annual rate of base salary of $233,300 in periodic installments in accordance with the Company’s customary payroll practices and applicable wage payment laws, but no less frequently than monthly. The Executive’s annual base salary, as in effect from time to time, is hereinafter referred to as “Base Salary”. ”


2.All other terms and conditions of the Employment Agreement remain in full force and effect.


3.This Amendment shall be governed by, and construed in accordance with, the laws of the Commonwealth of Pennsylvania without regard to conflicts of law principles.


4.This Amendment may be executed in one or more counterparts, each of which shall be deemed to be an original, but all of which shall be one and the same document. A signature to this Amendment transmitted electronically shall have the same authority, effect, and enforceability as an original signature.


IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written.


 By/s/ Jonathan Kaufman
 Name: Jonathan Kaufman
 Title: Chief Executive Officer


Signature:/s/ Jonathan Kaufman 
Print Name: Jonathan Kaufman